10-Q quarterly report · filed Nov 9, 2026

HARROW, INC. (HROW) Q3 2026 10-Q Quarterly Report

Short answer

HARROW, INC. (HROW) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $99M (up 38.6% year over year) with net income of $10M.

Q3 2026 key financials · XBRL

Revenue
$99M
+38.6% YoY · +40.5% QoQ
Net income
$10M
+856.6% YoY · +156.5% QoQ
Operating margin
11.6%
Gross margin
75.4%
EPS (diluted)
$0.26
+766.7% YoY · +156.5% QoQ

Source: XBRL data from the HARROW, INC. (HROW) Q3 2026 10-Q on SEC EDGAR. USD.

HARROW, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $99.297M, up $27.659M YoY from $71.638M
  • Best performer VEVYE, revenue $39.699M, up $17.073M YoY
  • Worst performer compounding, revenue $15.835M, down $4.221M YoY
  • Branded gross margin 79.3% vs 81.6% YoY, compounding margin 55.2% vs 59.0%
  • Cash $75.336M at September 30, operating cash flow nine-month use $27.363M; $48.915M financing inflow from 2030 Notes
  • TYRVAYA expected to contribute over $30M revenue in 2027, with approximately $20M annual operating expenses; licensor discussions remain unresolved

Risk Factors

  • New risk: TYRVAYA acquisition triggered potential VEVYE license conflict, requiring divestiture or rights termination
  • Financial risk: Up to $70,000,000 in TYRVAYA contingent milestone payments may remain payable
  • Regulatory risk: Proposed CMS GLOBE and GUARD models could increase ophthalmic-product rebates using international benchmarks
  • Market risk: Payor step edits, prior authorization, and formulary restrictions could reduce reimbursed patient access
  • Reporting risk: Inaccurate rebate and chargeback estimates could reduce revenues, margins, and cash flows

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other HARROW, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.